Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

The firm's artificial intelligence-based biomarker tools including Lunit Scope IO and Lunit Scope Universal IHC will be available across trials at the Center for Cancer Research.

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Researchers at the American College of Cardiology's annual meeting used proteomic approaches to uncover dysregulated signaling pathways in the disease.

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

AI models trained on optical coherence tomography scans to detect eye diseases are showing promise in diagnosing heart ...

NEW YORK – Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of a subcutaneous formulation of its PD-1 ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...